ASH-3Homo sapiens (Human)Cancer cell line
Also known as: ASH3
🤖 AI SummaryBased on 5 publications
Quick Overview
Human anaplastic thyroid carcinoma cell line with TERT promoter mutations and multidrug resistance.
Detailed Summary
ASH-3 is a human anaplastic thyroid carcinoma cell line derived from a 68-year-old female patient. It exhibits frequent somatic TERT promoter mutations, particularly C228T and C250T, which are associated with advanced thyroid cancers. The cell line shows multidrug resistance, with expression of MRP but not MDR-1 or MDR-3. ASH-3 is used in research to study thyroid cancer progression, genetic mutations, and drug resistance mechanisms. It has been characterized for its chromosomal abnormalities, immunocytochemical markers, and chemosensitivity profiles. ASH-3 is also utilized in studies examining the role of TERT mutations in tumor aggressiveness and therapeutic resistance.
Research Applications
Thyroid cancer progressionGenetic mutations in TERT promoterDrug resistance mechanismsChromosomal abnormalitiesImmunocytochemical marker analysis
Key Characteristics
Frequent TERT promoter mutations (C228T, C250T)Multidrug resistance (MRP expression)Chromosomal abnormalitiesImmunoreactivity for PCNA, HLA-class 1, cytokeratin, and FAS
Generated on 6/19/2025
Basic Information
| Database ID | CVCL_2856 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Thyroid gland[UBERON:UBERON_0002046] |
Donor Information
| Age | 68 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Anaplastic thyroid carcinoma |
|---|---|
| Lineage | Thyroid |
| Subtype | Anaplastic Thyroid Cancer |
| OncoTree Code | THAP |
DepMap Information
| Source Type | JCRB |
|---|---|
| Source ID | ACH-001443_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.His179Arg (c.536A>G) | Unspecified | - | PubMed=35297208 |
| MutationSimple | TERT | c.1-146C>T (c.250C>T) (C250T) | Unspecified | In promoter | PubMed=31068700 |
| MutationSimple | PTEN | p.Phe241fs (c.724dupG) | Homozygous | - | Unknown, Unknown, PubMed=30737244 |
| MutationSimple | NRAS | p.Gln61Arg (c.181A>G) | Heterozygous | - | Unknown, Unknown, PubMed=30737244 |
| MutationSimple | NRAS | p.Gln61Lys (c.181C>A) | Unspecified | Acquired during resistance selection process | PubMed=26214590 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
10,14
D13S317
12
D16S539
9
D18S51
13,17
D19S433
13,15.2
D21S11
28
D2S1338
19,23
D3S1358
15
D5S818
11,13
D7S820
11
D8S1179
16
FGA
20,22
Penta D
10,11
Penta E
5
TH01
9
TPOX
8,11
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Fagin J.A., Schweppe R.E.
Clin. Cancer Res. 25:3141-3151(2019).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Ibrahimpasic T., Ghossein R.A., Fagin J.A.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).